With Added Indication, Amarin Says Vascepa No ‘Fish Oil’ Like Omega-3s

In Amarin’s “education process” about indication as an add-on to statin therapy to help cut CV risk in high-risk patients, it “will also be emphasizing how Vascepa is different from” Rx drugs fenofibrate and niacin “and omega-3 mixtures,” says CEO John Thero.

Red heart and a stethoscope on backgrouund - Image

Amarin Corp. PLC doesn’t want its icosapent ethyl drug called a “fish oil product” now that it has approval for an additional cardiovascular risk indication that further differentiates it from fish oil dietary ingredients it contends are unfair competition.

The US Food and Drug Administration on 13 December approved Vascepa as an add-on to statin therapy to help cut...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Ingredients & Safety

More from HBW Insight